Literature DB >> 6229

SKF 525-A inhibition, induction, and 452-nm complex formation.

M K Buening, M R Franklin.   

Abstract

After administration of SKF 525-A to rats a portion of the cytochrome P-450 in hepatic microsomes was found in the reduced form as a stable complex absorbing at 452 nm. As much as 40% of the total cytochrome P-450 was bound in the complexed form after a single administration of SKF 525-A. The addition of potassium ferricyanide (50 muM) to hepatic microsomes from SKF 525-A-treated rats destroyed the complex and made the total cytochrome P-450 available for carbon monoxide binding. At early times after administration of SKF 525-A, when the amount of complexed cytochrome P-450 was maximum, mixed-function oxidase activities (p-nitroanisole O-demethylase and norbenzphetamine 455-nm complex formation) were greatly inhibited. Later, as the amount of complexed cytochrome P-450 slowly decreased, these mixed-function oxidase activities gradually returned and reached control values in about 48 hr. Induction with daily doses of SKF 525-A for several days increased total cytochrome P-450 content up to 5-fold, which was more than induction with phenobarbital, but this was evident only after destruction of the complex with ferricyanide. The maximum increase in uncomplexed cytochrome P-450 was only 2-fold. Treatment of these microsomal suspensions with ferricyanide enhanced ethylmorphine N-demethylase, p-nitroanisole O-demethylase and norbenzphetamine 455-nm complex formation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6229

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

2.  Effect of multiple administration of orphenadrine or mono-N-desmethylorphenadrine on cytochrome P-450 catalyzed reactions in the rat.

Authors:  A Bast; E M Savenije-Chapel; F A van Kemenade; L W Scheefhals; J Noordhoek
Journal:  Arch Toxicol       Date:  1983-10       Impact factor: 5.153

3.  Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol.

Authors:  H K Borys; G B Ingall; R Karler
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739

4.  In vitro studies on the metabolic fate of mifentidine, a novel histamine H2-receptor antagonist.

Authors:  K Pattichis; M Kajbaf; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.441

5.  Inhibition of the cytochrome P-450 multifunctional oxidase by N-propargyl analogs of SKF-525 A and acetylmethadol.

Authors:  J L Kraus; J J Yaouanc
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

6.  Interaction of ligands with cytochrome P-450. On the 442 nm spectral species generated during the oxidative metabolism of pyridine.

Authors:  P Hlavica; J Mietaschk; I Baden
Journal:  Biochem J       Date:  1982-05-15       Impact factor: 3.857

7.  Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450.

Authors:  D E Amacher; S J Schomaker; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

8.  Mutagenicity of quinones: pathways of metabolic activation and detoxification.

Authors:  P L Chesis; D E Levin; M T Smith; L Ernster; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Thyroid hormone regulation of heme oxidation in the liver.

Authors:  T J Smith; G S Drummond; I A Kourides; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Metal induction of haem oxygenase without concurrent degradation of cytochrome P-450. Protective effects of compound SKF 525A on the haem protein.

Authors:  G S Drummond; D W Rosenberg; A Kappas
Journal:  Biochem J       Date:  1982-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.